RxDoctor Payments Data

James Chapman, MD

Interventional Cardiology · Grove, OKNPI 1124030002

Payments from drug & device makers

$3,285in general payments, 2019–2025

Across 164 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$729
  • Pfizer$467
  • Novartis$419
  • Abiomed$414
  • Amgen$235
  • Boston Scientific$145
  • plus $876 from 15 others

What the payments were for

  • Food & beverage$3,26399%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,285 in reported general payments places this provider in the 25th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$300,399
Medicare patients
1,347
Services billed
3,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban359$363,031
EntrestoSacubitril/Valsartan83$108,253
Repatha SureclickEvolocumab39$35,324
XareltoRivaroxaban21$27,789
Repatha SyringeEvolocumab21$14,032
Metoprolol Succinate589$7,004
Atorvastatin Calcium237$2,436
Nebivolol Hcl35$2,256
Losartan Potassium177$1,804
Rosuvastatin Calcium109$1,760
ClopidogrelClopidogrel Bisulfate176$1,550
Amiodarone Hcl94$1,178
Diltiazem 24hr Er (Cd)Diltiazem Hcl49$1,026
Spironolactone115$1,017
Amlodipine Besylate204$973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$467$363,031359 claims
NovartisEntresto$419$108,25383 claims
Johnson & JohnsonXarelto$92$27,78921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 110 interventional cardiology providers in Oklahoma.

Other interventional cardiology in Grove

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →